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Abstract
BACKGROUND: Most of bladder cancers are proven to be of urothelial origin (transitional cell carcinomas). Above 75% 
of them are of non-muscle invasive bladder cancer (NMIBC) type at presentation and the remainder are MIBC. Recent 
studies suggest that both are most probably two different categories based on both the histopathological and molecular 
features. The comprehensive understanding of the biomarkers expression in both categories will help in understanding 
the molecular event underlying each of them and may provide possible chances for targeted therapeutic options.
AIM: This study aims to study the differential expression of both E-cadherin and human epidermal growth factor 
receptor-2 (HER2) in the two categories of bladder cancer NMIBCs and MIBCs.
MATERIALS AND METHODS: A total of 40 blocks were collected retrospectively from cases of cancer bladder, 
segregated as 20 cases NMIBCs and 20 cases MIBCs, subjected for E-cadherin and HER2 immunostaining.
RESULTS: E-cadherin showed positive expression in 65% of cases of NMI group and in 10% of the MI group, with 
high statistical significance (p < 0.001). Regarding HER2, positive expression was seen in 25% of NMI cases and 
in 90% of MI cases, with statistical significance (p < 0.001). Comparison of the results of both markers and their 
correlation per case showed that 90% of tumors with muscle invasion were E-cadherin negative and HER2 positive.
CONCLUSION: The significant association of loss of E-cadherin immunohistochemistry expression and positive 
HER2 overexpression in MIBC versus NMIBC figured out more differences between the two categories and added 
to the understanding of their biology. The possibility of validation of HER2-targeted therapy in MIBC cases is now 
strongly suggested.
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Introduction
Bladder cancer is one of the most common 
cancers and the most common cancer of the urinary 
tract with above 350,000 new cases per year and more 
than 140,000 deaths per year worldwide [1]. In Western 
countries, it ranks the fifth among men cancers [2]. In 
Egypt, bladder cancer ranks second among the most 
commonly diagnosed malignancies in men [3]. Most 
of bladder cancers (above 90%) are proven to be of 
urothelial origin (transitional cell carcinomas). Above 
75% of them are of non-muscle invasive bladder cancer 
(NMIBC) type at presentation, and the remainder are 
MIBC [4].
Recent studies have evolved a model suggests 
that both NMBCs and MIBCs are most probably two 
different categories based on both the histopathological 
and molecular features [5]. Biologically; in most cases, 
the urothelial carcinoma cells do not have even the 
ability to invade. The clones that acquired this ability 
will definitely show different mutations and hence 
different molecular profile [6]. Moreover, another theory 
was introduced proposing that papillary NMIBC most 
likely develop through urothelial cell hyperplasia and 
gaining branching vascular channels, while MIBC is 
thought to develop through flat dysplasia – carcinoma 
in situ consequence. The biological and molecular 
features of each are, therefore, highly distinct [7]. 
The comprehensive understanding of the biomarkers 
expression in both categories will help in understanding 
the molecular event underlying each of them and may 
provide possible chances for targeted therapeutic 
options. E-cadherin is one of calcium-dependent 
transmembrane cadherin family member that is 
normally presents in epithelial cells and mediates cell 
adhesion [8]. It is now well understood that E-cadherin 
is a key stone in what is called epithelial mesenchymal 
transition (EMT), which is the basic step in tumor 
progression and both local and distant metastasis in 
different cancers [9].
However, the exact role of E-cadherin in 
cancer is still controversial and its role in cancer is still 
not well understood in each individual type of cancer. 
Although previous data suggested that E-cadherin acts 
as a tumor suppressor that is lost in advanced cancers, 
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yet recent researches have confirmed that it has, as 
well, a cancer promoter function, as in cancer breast, 
where it shows overexpression in advanced cases [10]. 
The human epidermal growth factor receptor-2 (HER2/
neu) is a transmembrane glycoprotein and a well-
known member of the EGF family of tyrosine kinase 
receptors which is encoded by the HER2/neu proto-
oncogene [11]. In normal cells, HER2 is involved in 
many biological processes including proliferation, 
differentiation, and angiogenesis [12]. In cancer cells, 
HER2 has been noticed to increase dramatically, and 
hence overexpressed in several malignancies [13], 
and some recent reports pointed to the possible 
involvement of HER2 in EMT in some cancers as breast 
cancer [14]. In bladder cancer, the role of HER2 is still 
controversial [11].
Some studies have highlighted that cadherin-
driven EMT function depends at least partially in their 
signaling pathways inside the tumor cells on ErbB family 
molecules [15]. Both E-cadherin and HER2 expression 
can modify the patient line of management and be a 
target for targeted therapy [16], [17].
The aim of this work was to study the 
differential expression of both E-cadherin and HER2 
in the two categories of bladder cancer NMIBCs and 
MIBCs, aiming to better understanding of the biological 
differences between the two categories as well as to 
determine the possible role of targeted therapy in both 
groups.
Materials and Methods
Cases
A total of 40 blocks were collected 
retrospectively from cases of cancer bladder in Nasr 
Institute for treatment and research from cases in 2013 
to 2018 as; 20 cases NMIBCs and 20 cases MIBCs.
Two unstained 3–5 µm thick sections were 
prepared from each block for further immunostaining.
Immunohistochemistry
Immunohistochemical staining was done using 
the EnVision (USA) method as follows:
Deparaffinization in xylene and rehydration 
in graded alcohol were done; then, the endogenous 
peroxidase activity was blocked by incubating the 
slides in 0.3% hydrogen peroxide for 10 min. Dako 
target retrieval solution (pH 6.0) was used for 20 min; 
then, the slides were incubated for 60 min at room 
temperature with a rabbit polyclonal anti-HER2/
neu (Lab Vision Corp., Fremont, CA, USA, at 1:200 
dilution), the Abcam mouse monoclonal Twist antibody 
(1:100), and a mouse monoclonal antibody E-cadherin 
(Clone: NCH-38, Dako, USA). Slides are then washed 
with two changes of phosphate buffer saline, stained 
with secondary antibody (Dako, USA) for about 15 min 
at room temperature, then rinsed in the buffer. Slides 
were incubated for 1 h at room temperature. Positive 
control slides were also stained in the same run (normal 
urothelium was used as positive control for E-cadherin 
and intraductal carcinoma of breast tissues was used 
as positive control for HER2/neu).
E-cadherin was evaluated as follows [18]: 
Uniformly positive (+): More than 90% of tumor cells 
are stained (membranous), heterogeneous (±): More 
than 10 and <90% of the tumor cells are positive 
(membranous and cytoplasmic), and negative: <10% of 
the tumor cells were positive.
The positive uniform membranous staining 
pattern of the tumor cell is considered normal (positive) 
expression. Negative and heterogeneous staining 
pattern were considered to be negative (aberrant).
The original HercepTest™ was used for 
HER2 protein immunohistochemical detection. HER2 
expression was classified according to the modified 
DAKO criteria as follows: Negative (scores 0/1+), 
equivocal (score 2+), and positive (score 3+), the 
cutoff for score 3+ is more than 10% strongly positive 
cells. According to Kolla et al., 2008 [19], sections with 
scores 2 and 3 were considered as positive for HER2/
neu.
Statistical analysis
Data were coded and entered using statistical 
package SPSS version 21. Data were summarized 
using numbers and percentage for qualitative variables. 
Comparisons between the two studied groups 
were done using Chi-square test for the qualitative 
variables. Logistic regression analysis was done to 
test for significance predictors of muscle invasion in 
bladder cancer. p ≤ 0.05 was considered as statistically 
significant.
Results
The study included 40 retrogressive cases. 
Cases are divided into two groups of 20 cases each:
Group 1: Urothelial carcinoma with negative 
muscle invasion included 8 females and 12 males, with 
the age ranged from 51 up to 65 with mean 56 years.
Group 2: Urothelial carcinoma with positive 
muscularis propria invasion included 4 females and 
16 males, with the age ranged from 58 up to 72 with 
mean 66 years.
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Immunohistochemical results
E-cadherin (Figure 1 and Table 1) showed 
positive expression in 65% of cases of NMI group 
(13 case) and in 10% of the MI group (2 cases), with 
high statistical significance (p < 0.001).
Figure 1: Results of E-cadherin: (a) ×10, (b) ×40, (c) ×200. Section 
from a case of non-muscle invasive bladder cancer (MIBC) showing 
positive expression. (d) ×10, (e) ×40, (f) ×200. Sections from high-
grade MIBC showed aberrant (negative) immunostaining
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According to the OR (0.06), E-cadherin 
expression is associated with lesser occurrence of 
muscle invasion.
Table 1: Results of immunohistochemical studies for 
E-cadherin and HER2 in the studied groups
Marker Status MI n (%)
n=20
NMI n (%)
n=20
Total n (%)
n=40
E-cadherin Positive 2 (10) 13 (65) 15 (37.5)
E-cadherin Negative 18 (90) 7 (35) 25 (62.5)
HER2 Positive 18 (90) 5 (25) 23 (57.5)
HER2 Negative 2 (10) 15 (75) 17 (42.5)
Regarding HER2 (Figure 2 and Table 1), 
positive expression was seen in 25% of NMI cases 
(5 cases) and in 90% of MI cases (18 cases), with 
statistical significance (p < 0.001).
Positive Her2 is found to be associated with 
increase the risk of muscle invasion 27 folds than 
negative results (OR = 27.0).
Comparison of the results of both markers and 
their correlation per case showed that 90% of tumors 
with muscle invasion were E-cadherin negative and 
HER2 positive (Figure 3, Table 2).
Figure 2: Results of HER2/neu immunostaining in the two studied 
groups. (a) ×10, (b) ×40, (c) ×200. Sections from high-grade muscle 
invasive bladder cancer (MIBC) showed strong diffuse membranous 
HER2/neu immunostaining, considered positive. (d) ×10, (e) ×40, 
(f) ×200. Sections from low-grade non-MIBC showed aberrant 
heterogeneous HER2/neu immunostaining, considered negative
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f
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Figure 3: Combined results of E-cadherin and HER2 in the studied 
cases
On the other hand, 45% of tumors without 
muscle invasion were E-cadherin positive and HER2 
negative.
The logistic regression test showed that the 
positivity of Her2 could predict muscle invasion.
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Moreover, similarly, the positivity of E-cadherin 
is considered a good prediction of non-muscle invasion.
Discussion
Bladder cancer was of great attention in Egypt 
due to its increasing rates and high treatment-associated 
morbidity [20]. Segregation of bladder urothelial cancer 
in two categories of NMIUB and MIUB is now becoming 
a trend that leads to study each category as a separate 
identity with increasing needs for deep understanding 
the biological and underlying biomarker expression in 
each group.
In this study, we examined E-cadherin and HER2 
in both categories to assess their possible prognostic role 
and the applicability of targeted therapy in each.
In the present study, E-cadherin positivity was 
seen in 65% of non-muscle invasive group, opposing to 
10% only in the muscle invasive group. Agreeing with 
our results, Jäger et al., 2010 [21], showed decreased 
positive E-cadherin staining in bladder cancer 
advanced stages and grades as well. Matching findings 
were also reached by Baumgart et al., 2007 [22], who 
demonstrated notable decrease in E-cadherin marker 
staining in their cases from NMIBC to MIBC in 572 UBC 
cases. D’Andrea et al. (2018) [23] examined E-cadherin 
as a proposed biomarker for recurrences prediction in 
NMIBC and although its positivity in most of the cases, 
E-cadherin failed to predict the recurrences in this 
study. Otto et al., 2017 [18], approved E-cadherin as a 
prognostic marker that is lost in progressive cases with 
above 75% positivity rate in their cases.
In their study, Kashibuchi et al., 2007 [24], 
compared the expression of E-cadherin and β-catenin in 
non-invasive and early invasive tumors versus invasive 
tumors. They showed a statistically significantly loss of 
both E-cadherin and β-catenin receptors in advanced 
stages and grades. Hu et al., 2011 [25], got similar 
findings; they studied 72 cases of UBC patients and 
confirmed increase aberrant staining (decreased 
positivity) of both E-cadherin and β-catenin with increase 
the tumor stage and its grade. Such mimicking results 
highlight the postulation of the inverse proportional 
relation of E-cadherin expression and muscle invasion.
In our study, 90% of the cases of MIUBCs 
showed positive overexpression for HER2/neu, with 
score +3, in contrast to 25% of NMIUCs, with significant 
association of HER2 expression with muscle invasive 
cases. The expression in the positive cases was 
diffuse (70–100% of tumor cells). These results agree 
with Hammam et al., 2015, study [26], which showed 
equivocal Her2 expression (score 2, which is considered 
negative in their study) in 23% of NMIBC cases and 
positive (score 3) expression in 43% and 46% of T1 and 
T2-3 tumors, respectively, with statistical significance.
Kolla et al., 2008 [19], showed positive 
expression in more than 70% of the MIBC cases and 
suggested that HER2 expression might provide an 
additional significant prognostic information for patients 
with bladder cancer. The diffuse strong expression of 
the HER2 in the positive cases was also described by 
Tschui et al., 2015 [27], in their study, they reported 
strong diffuse expression in 77% of the muscle invasive 
cases, they considered this a good indicator for the 
promising results of targeted therapy.
On the other hand, some studies denied 
the relation between HER2 expression and tumor 
progression. Latif et al., 2003 [28], showed rates of 76 
and 52% in stages Ta/T1 and T2 tumors, respectively, 
with insignificant difference (p = 0.06), and therefore, 
they concluded that increased HER2 protein 
overexpression may occur before tumor progression. 
Moreover, similarly, Agrawal et al., 2015 [29], noticed 
the overexpression of HER2 in NMIBCs and even more 
than in cases of MIBC.
From their study on bladder cancer cases, 
Mohammed et al., 2016 [7], concluded that HER2 
overexpression is associated with muscle invasion and 
is predictor for poor survival and disease progression. 
As we did, they propose that HER2 is an independent 
risk factor for tumor progression. In the same regards, 
Ding et al., 2015 [30], suggested Her2 overexpression 
to be a risk factor for the detection of aggressive 
biological tendency in NMIBC.
HER2 expression in bladder cancer was very 
heterogeneous throughout different studies and this 
area is still poorly defined [31]. The notable variability in 
results between different studies as well as between the 
cases among each studied group in our results can be 
eventually explained in the context of genetic level and 
the newly named molecular classification of the bladder 
tumors into luminal and basal, as was suggested by 
Powles et al., 2016 [12].
We agree in this explanation together with the 
facts that the variability between studies in studying the 
gene expression using FISH technique versus the study 
of protein expression using immunohistochemistry 
technique added to the complexity of the comparing the 
results of different studies. Similarly, the interpretation 
of immunohistochemistry results (considering score 2 
as negative or positive in results) markedly affected the 
results among different studies.
The association of HER2 overexpression 
in MIUCs over the NMIUCs relates well with the 
Table 2: Combined results of both E-cadherin and HER2 in the 
studied cases
Studied group MI n (%) NMI n (%) Total n (%)
Results n=20 n=20 n=40
Both negative 0 (0) 6 (30) 6 (15)
E-cad −ve and HER2 +ve 2 (10) 9 (45) 11 (27.5)
E-cad +ve and HER2 −ve 18 (90) 1 (5) 19 (47.5)
Both positive 0 (0) 4 (20) 4 (10)
Total 20 (100) 20 (100) 40 (100)
E-cad: E-cadherin, −ve: Negative, +ve; Positive.
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proposed fact that Her 2 overexpression is associated 
with bad prognosis and tumor progression Nagata 
et al., 2016 [32], through activating intracellular 
pathways enhancing tumor cells proliferation, 
motility, and invasion [13]. Cases of NMIBCs that 
display the overexpression may, therefore, carry 
bad prognostic indicator and may be considered a 
risk factor that requires even early cystectomy [33]. 
The controversial results of HER2 in bladder cancer 
was very obvious when Sanguedolce et al., 2018 [5], 
excluded HER2 from the prognostic factors of bladder 
cancer and denied its possible role as a targeted 
therapy, while in the same year, Sanguedolce et al., 
2018, suggested HER2 as a predictor for the disease 
outcome [34].
From their study, Kiss et al., 2017 [13], stated 
that although MIBC showed the third highest rates in 
ERBB2 amplification and HER2 overexpression (after 
both breast and gastric cancers), yet the anti-HER2 
treatments in MIBC have not shown encouraging 
results. They attributed this to the possible variation 
in the recently recognized bladder cancer molecular 
subtypes.
According to the results of the present study, 
the correlated results of both markers in the cases 
together with the logistic regression study pointed to 
the proposed idea that the advanced stages in bladder 
cancer may be correlated with loss of E-cadherin 
positivity and acquiring Her2 positivity.
Reviews had proved that EMT is usually 
associated with downregulation or total loss of 
E-cadherin protein expression (being an adhesion 
molecule and epithelial cell-cell junction marker). This 
step is also marked by upregulation of N-cadherin 
protein (mesenchymal marker). The function of the 
later is noted to be depending on and related to HER2 
at least partially. We propose that the notable inverse 
relation between E-cadherin expression and HER2 
overexpression might be related to the role of each 
of them in EMT, which is a crucial step in all cancers’ 
progression [15].
Conclusion
The significant association of loss of E-cadherin 
immunohistochemistry expression and positive Her2 
overexpression in MIBC versus NMIBC figured out 
more differences between the two categories and 
added to the understanding of their biology. Both Her2 
overexpression and E-cadherin negativity are proposed 
as risk factors for occurrence of muscle invasion in 
small superficial biopsies. The possibility of validation 
of Her2-targeted therapy in MIBC cases is now strongly 
suggested.
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